Thyrocare Technologies Limited reported a 128% year-on-year jump in consolidated profit after tax (PAT) to Rs. 48.70 crore for Q4FY26, supported by strong growth in its pathology business, rising test volumes, and continued expansion into specialty diagnostics.

The company posted consolidated revenue of Rs. 223.95 crore for the quarter ended March 31, 2026, registering 20% year-on-year growth, while EBITDA increased 31% to Rs. 75.09 crore.

Thyrocare processed 59 million tests during Q4FY26, marking a 29% year-on-year increase and reinforcing its position as one of India’s largest diagnostic test volume processors. The pathology business recorded strong traction with franchise revenue growing 21% year-on-year and partnership revenue increasing 23%.

During the quarter, the company strengthened its specialty diagnostics portfolio by launching advanced allergy testing with more than 250 SKUs on the Phadia platform and entered the genomics segment through a state-of-the-art laboratory and launch of Non-invasive Prenatal Testing (NIPT). The company said it is also undertaking a phased expansion of its genomics and precision diagnostics test menu.

For FY26, Thyrocare reported consolidated revenue growth of 21% year-on-year to Rs. 829.04 crore, while PAT rose 81% to Rs. 162.85 crore. EBITDA for the full year increased 38% to Rs 262.04 crore, and annual test volumes grew 23% to 209.6 million tests.

The company also maintained Six Sigma quality standards during the quarter, reducing complaints per million tests by 34% year-on-year to 3.1, with an average turnaround time (ATAT) of 3.43 hours from sample receipt.

 Rahul Guha, MD & CEO, Thyrocare Technologies Ltd, said, “Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India.”